Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Reports Q3 Revenues of $4.2M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics today updated its third-quarter financial results, reporting revenues of $4.2 million for the three months ended Sept. 30.

For the 2009 third quarter, the Mountain View, Calif.- based sequencing service firm had recorded no revenues.

In an amended S-1 form filed with the US Securities and Exchange Commission, the company said it had a loss of $20.5 million, compared to a loss of $9.2 million a year ago. It added it had cash and cash equivalents of $10.5 million as of Sept. 30, and a backlog that is expected to result in $9 million in revenues over the next 12 months.

The company said that it had 167 employees at the end of the third quarter and plans to expand its production, sales and marketing, and R&D programs and to hire additional staff to support its expansion.

The firm, which filed a preliminary prospectus for its initial public offering during the summer, is expected to complete its IPO this week, according to various news reports.

Last month, Complete Genomics raised the proceeds target for its IPO to $96.6 million by offering 6 million shares at a price of between $12 and $14 per share. The company expects to raise net proceeds of $69.3 million, or $80.2 million if the offering's underwriters exercise their over-allotment option in full.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.